Cargando…
Myasthenia Gravis: Pathogenic Effects of Autoantibodies on Neuromuscular Architecture
Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction (NMJ). Autoantibodies target key molecules at the NMJ, such as the nicotinic acetylcholine receptor (AChR), muscle-specific kinase (MuSK), and low-density lipoprotein receptor-related protein 4 (Lrp4), that lead by a range...
Autores principales: | Koneczny, Inga, Herbst, Ruth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678492/ https://www.ncbi.nlm.nih.gov/pubmed/31269763 http://dx.doi.org/10.3390/cells8070671 |
Ejemplares similares
-
Myasthenia Gravis With Antibodies Against Muscle Specific Kinase: An Update on Clinical Features, Pathophysiology and Treatment
por: Cao, Michelangelo, et al.
Publicado: (2020) -
Autoantibodies to Agrin in Myasthenia Gravis Patients
por: Zhang, Bin, et al.
Publicado: (2014) -
Autoantibodies in Japanese patients with ocular myasthenia gravis
por: Nagaishi, Akiko, et al.
Publicado: (2020) -
Editorial: Molecular Mechanisms Underlying Assembly and Maintenance of the Neuromuscular Junction
por: Herbst, Ruth, et al.
Publicado: (2021) -
Myasthenia Gravis: Autoantibody Specificities and Their Role in MG Management
por: Lazaridis, Konstantinos, et al.
Publicado: (2020)